Is SNDX a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Syndax Pharmaceuticals (SNDX) rests on Revuforj moving from KMT2A into the far larger NPM1 population: The original November 2024 approval covered KMT2A-rearranged acute leukemia, a genuinely rare subset. The bear case rests on revuforj no longer has the menin inhibitor class to itself. Analysts covering it publish targets from $17.00 to $57.00 against a $8.72 share price on November 20, 2026, so even the professionals disagree by 118% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
SNDX key stats
At $8.72 on November 20, 2026, Syndax Pharmaceuticals (SNDX) has a market cap of $785M.
- Market cap
- $785M
- Beta
- 0.45
Market cap, P/E and yield are measured at the $8.72 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Syndax Pharmaceuticals (SNDX)?
The last two weeks for Syndax Pharmaceuticals, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- SNDX closed at $8.72 on November 20, 2026, down 7.7% over the past five trading days (from $9.45).
Syndax Pharmaceuticals filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Syndax Pharmaceuticals (Nasdaq: SNDX) sells two approved medicines and funds a pipeline behind them. Revuforj (revumenib) is an oral menin inhibitor, approved by the FDA on November 15, 2024 for relapsed or refractory acute leukemia carrying a KMT2A translocation in patients one year and older, then expanded on October 24, 2025 into relapsed or refractory AML with a susceptible NPM1 mutation. Syndax owns it outright in the US, licensed originally from Vitae Pharmaceuticals, now an AbbVie subsidiary, and books its sales as product revenue. Niktimvo (axatilimab-csfr) is a first-in-class antibody against the CSF-1 receptor, approved in August 2024 for chronic graft-versus-host disease after at least two prior lines of systemic therapy in patients weighing 40kg or more. It was in-licensed from UCB Biopharma in 2016 and then partnered with Incyte in September 2021 under a worldwide co-development and co-commercialization agreement. Incyte runs the commercial engine and records the sales; Syndax takes half the net commercial profit. In the third quarter of 2026 Revuforj generated about $61M of net product revenue on roughly 1,700 prescriptions, while Niktimvo generated about $67M of net sales, of which $22.6M reached Syndax as collaboration revenue. The company employed about 298 people at last count. The financial picture is a launch curve running into a fixed cost base. Total revenue went from $23.7M in 2024 to $172.4M in 2025 to ~$290M for the twelve months to September 30, 2026, and the third quarter alone was $83.3M, up 82% year over year and a little ahead of the ~$81.9M consensus. Operating expenses barely moved over that stretch: total opex was $211.8M for the first half of 2026 against $210.9M a year earlier, and management has reaffirmed full-year R&D plus SG&A to approximately $400M excluding roughly $50M of non-cash stock compensation, down from $438.5M in 2025. Operating loss narrowed accordingly, from $153.1M in the first half of 2025 to $74.2M in the first half of 2026, though the net loss held near $49M a quarter in both the second and third quarters. What the market is paying for sits mostly outside those numbers. Revuforj and Niktimvo are both approved only in later-line settings, and the registrational trials that would move revumenib into newly diagnosed AML (EVOLVE-2 and REVEAL-ND) and axatilimab into frontline cGVHD are still reading out, and the Phase 2 frontline cGVHD combination with ruxolitinib has been pushed from late 2026 to the first quarter of 2027. One expansion has already closed: on October 12, 2026 Syndax reported that the 145-patient MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint (annualized decline in forced vital capacity), and the company does not plan further development in IPF. The stock fell about 16% after hours on the news. The second- and third-quarter losses of $0.55 a share were both wider than consensus (~$0.44 and ~$0.48). At ~$8.95 on November 20, 2026, down ~58% for the year, ~55% over three months and ~33% over the past month, the equity is capitalised around $806M, with about $551M of cash and investments at September 30, 2026 against roughly $589M of debt, most of it the Royalty Pharma liability and the convertible notes.
The bull case: what would have to be true for $57.00
The most optimistic published target on SNDX is $57.00, +553.7% from the $8.72 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Revuforj moving from KMT2A into the far larger NPM1 population
The original November 2024 approval covered KMT2A-rearranged acute leukemia, a genuinely rare subset. The October 24, 2025 label expansion added relapsed or refractory AML with a susceptible NPM1 mutation, which is roughly a third of adult AML and several times the size of the first indication. The revenue trace since then shows the effect: $44.2M in the fourth quarter of 2025, $48.9M in the first quarter of 2026, $54.7M in the second and about $61M in the third (up 90% year over year and 11% sequentially), with prescriptions of about 1,700 in the latest quarter, up 13% sequentially, and roughly 300 new patients. Management has described a run of consecutive quarters of double-digit net revenue and prescription growth, and attributes part of it to longer average treatment duration as more patients stay on drug in the post-transplant setting.
2. Niktimvo, where Syndax sees half the profit and none of the sales line
Niktimvo net sales were about $67M in the third quarter of 2026, up 47% year over year and 12% sequentially, after $60.3M in the second quarter and $151.6M across all of 2025. Syndax's reported figure was $22.6M, helped by a one-time adjustment that lifted the profit share to about 34% of net sales; management guides that ratio to the low-to-mid 30s going forward, because the agreement splits net commercial profit (net product revenue minus cost of sales and commercial expenses) rather than revenue. Two consequences follow. Syndax's line is inherently lumpier than the drug's own trajectory, since a quarter of heavier commercial investment by Incyte compresses the profit share even while sales grow. And a screener computing gross margin or price-to-sales on Syndax will be working from a number that has already had manufacturing and selling costs deducted from half the franchise. The October 2026 IPF failure removes the largest non-transplant market axatilimab was being tested in, so Niktimvo's growth case now runs through cGVHD alone: the Phase 2 combination with ruxolitinib in newly diagnosed patients (topline now expected in the first quarter of 2027, delayed from late 2026) and a Phase 3 combination with steroids (readout expected in early 2028).
3. Frontline AML, which is what the valuation is actually about
Every approved use of Revuforj today is in relapsed or refractory disease, where patients are few and treatment durations are short. The company has two registrational Phase 3 trials aimed at newly diagnosed patients: EVOLVE-2, testing revumenib with venetoclax and azacitidine in NPM1-mutated and KMT2A-rearranged AML patients unfit for intensive chemotherapy, run with the HOVON network, and REVEAL-ND, testing revumenib with intensive chemotherapy in newly diagnosed NPM1-mutated AML. Supporting investigator-led work has been encouraging, including a Journal of Clinical Oncology publication in June 2026 from the Phase 1/2 SAVE trial reporting an 88% overall response rate and 71% composite complete remission in 42 heavily pretreated patients. Whether that translates into a registrational frontline result is the difference between a couple of hundred million in annual sales and something much larger. EVOLVE-2 uses complete remission rate as a dual primary endpoint, measured against historical controls in the low-to-mid 30s percent. Syndax has 19 abstracts accepted at ASH 2026, seven of them oral presentations, and is holding an investor event on December 14, 2026 alongside the meeting, where longer follow-up from the BEAT AML and SAVE frontline combinations is planned. After the IPF setback, more of the company's value hangs on these trials.
4. Expenses flat while revenue triples
Syndax spent $438.5M on R&D and SG&A in 2025 building out two simultaneous launches. The 2026 guide, reaffirmed in November, is approximately $400M excluding around $50M of estimated non-cash stock compensation, so the absolute spend is coming down while revenue rises. Second-quarter SG&A fell to $41.5M from $43.8M as the 2025 launch costs did not repeat, and R&D rose only to $68.0M from $62.2M despite the frontline trial expansion. Cash used in operating activities dropped from $183.0M in the first half of 2025 to $80.6M in the first half of 2026, and cash and investments ended September at about $551M, down from $575.1M in June. Management states it expects existing cash plus product, collaboration and interest income to carry the company to profitability, though no date is attached to that.
The bear case: what would have to be true for $17.00
The most pessimistic published target is $17.00, +95.0% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Syndax Pharmaceuticals is worth if the risks below bite instead of the drivers above.
Revuforj no longer has the menin inhibitor class to itself. Kura Oncology and Kyowa Kirin won FDA approval for ziftomenib (Komzifti) in November 2025 in relapsed or refractory NPM1-mutated AML, the same population Syndax entered three weeks earlier, and began selling on November 21, 2025. Komzifti is dosed once daily. Both labels carry boxed warnings, including differentiation syndrome and QTc prolongation, so the competition is likely to be fought on dosing convenience, payer access and combination data rather than on a clean safety separation. Kura's partner paid $330M upfront with up to $1.1B in milestones, which funds a serious commercial effort against a Syndax field force that is already carrying two products. Johnson & Johnson and Sumitomo also have menin inhibitors in development. The balance sheet is the second issue. Total stockholders' equity was $15.1M at June 30, 2026 against $688.6M of liabilities, and the accumulated deficit stands at about $1.6B; trailing net losses of ~$209M have eroded that thin cushion further since. The financing is unusual in shape: a $350M upfront from Royalty Pharma in November 2024 that sells 13.8% of US Niktimvo net sales with aggregate payments capped at $822.5M, accounted for as debt, plus $250M of 2.25% convertible senior notes due June 2031 issued in June 2026 at a conversion price near $24.76. Royalty interest expense alone was $12.1M in the second quarter and $24.0M for the half, and it grows as Niktimvo grows. If Niktimvo performs, Syndax pays back up to 2.35 times what it received. The converts add about 10.1M potential shares against 89.4M outstanding. Beyond that, revenue depends on two products in narrow later-line indications, both under UCB and AbbVie-related royalty obligations, with the frontline expansions still unproven. The first quarter of 2026 already showed how sensitive the line is to the January payer reset, falling to $64.9M from $68.7M in the fourth quarter of 2025 despite underlying demand growth. Pipeline risk has already shown up once. The MAXPIRe Phase 2 trial in idiopathic pulmonary fibrosis (145 patients, 26 weeks, axatilimab 0.3 mg/kg every two weeks against placebo) missed its primary endpoint on October 12, 2026, though safety was comparable to placebo. Syndax said the result does not affect trials in other indications, and BofA cut its target to $23 from $26 while keeping a Buy rating. The second readout that mattered, axatilimab plus ruxolitinib in frontline cGVHD, then slipped to the first quarter of 2027, and the company is also going through a chief financial officer transition. The third-quarter loss of $0.55 a share missed the ~$0.48 consensus, the second miss in a row, and the shares fell from ~$13.11 on October 16 to ~$8.95 on November 20, 2026, close to the 52-week low of ~$8.41. UBS cut its target to $31 from $33 on November 20 while keeping a Buy rating.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SNDX already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on SNDX
11 analysts cover SNDX, with an average target of $34.00 (+289.9% against $8.72) and a split of 12 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SNDX forecast and price target page.
How is SNDX valued?
Market cap, P/E and dividend yield at today's price are in the SNDX key stats above. The business figures below come from Syndax Pharmaceuticals's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$289.7M for the twelve months to September 30, 2026, against $172.4M in fiscal 2025 and $23.7M in fiscal 2024. The quarterly path was $68.7M in 4Q25, $64.9M in 1Q26 (a sequential dip driven by the January payer and gross-to-net reset, not by demand), $72.8M in 2Q26 and $83.3M in 3Q26, the last of which was up ~82% year over year.
- Product mix (the line that misleads screeners): Of 3Q26's $83.3M, about $61M was Revuforj net product revenue and $22.6M was collaboration revenue representing Syndax's 50% share of Niktimvo net commercial profit, on about $67M of Niktimvo net sales. Combined branded sales of the two medicines were therefore ~$128M in 3Q26 and over $275M across full-year 2025 ($124.8M Revuforj plus $151.6M Niktimvo), well above the reported revenue line.
- Earnings and EPS: Net loss of $49.4M, or $0.55 per share, in 3Q26, level with 2Q26; trailing twelve-month net loss of ~$209.5M, or ~$2.37 per share. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. There is no P/E, and there has never been an annual profit; consensus has the loss narrowing to ~$0.65 a share in 2027.
- Operating expenses and guidance: Full-year 2026 guidance, reaffirmed with third-quarter results, is approximately $400M of R&D plus SG&A excluding ~$50M of estimated non-cash stock compensation, down from $438.5M actual in 2025. First-half opex was $211.8M against $210.9M a year earlier, so spend is roughly flat while revenue keeps climbing. Trailing operating margin is about -62%.
- Cash flow and balance sheet: Cash, cash equivalents and investments of about $551M at September 30, 2026, down from $575.1M at June 30 and up from $394.1M at December 31, 2025 after the $250M convertible issue. Trailing operating cash burn was ~$177M and free cash flow ~-$113M. Total debt of ~$589M, mainly the Royalty Pharma royalty financing liability and the 2.25% convertible notes due 2031; stockholders' equity was just $15.1M at June 30, 2026.
- Market pricing: ~$8.95 a share on November 20, 2026 for a market capitalisation of ~$806M, against a 52-week range of $8.41 to $25.59; the stock is down ~58% year to date, ~55% over three months and ~47.5% over one year. That works out to ~2.8x trailing sales. No dividend and no P/E.
As of November 2026: Roughly 2.8 times trailing sales is a low multiple for a biotech growing revenue at ~82%, and the reasons are visible in the structure and the pipeline more than the growth rate. Half the franchise arrives as a profit share, the Royalty Pharma instrument skims 13.8% of US Niktimvo sales before anything reaches Syndax, both drugs are approved only in later-line settings, the October 2026 IPF failure removed one route to a much larger market, and the frontline cGVHD readout has moved into 2027. At ~$806M, the market value is only about $255M above the ~$551M of cash and investments, while ~$589M of debt sits ahead of shareholders. Eleven covering analysts carry a mean target near $34, a frontline-expansion number and not a run-rate one.
How do you decide if SNDX is a buy?
Whether SNDX is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SNDX indirectly through an index or sector ETF before adding more.
What would change your mind on SNDX
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Revuforj moving from KMT2A into the far larger NPM1 population stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: revuforj no longer has the menin inhibitor class to itself fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the SNDX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SNDX against your real portfolio and see your actual exposure before deciding.
Your questions about Syndax Pharmaceuticals
Ask Walnut's AI anything about SNDX and see how it fits what you own.
FAQ
Is SNDX a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Revuforj moving from KMT2A into the far larger NPM1 population, with revenue (ttm) at ~$289.7M for the twelve months to September 30, 2026, against $172.4M in fiscal 2025 and $23.7M in fiscal 2024. The quarterly path was $68.7M in 4Q25, $64.9M in 1Q26 (a sequential dip driven by the January payer and gross-to-net reset, not by demand), $72.8M in 2Q26 and $83.3M in 3Q26, the last of which was up ~82% year over year.. The bear case rests on revuforj no longer has the menin inhibitor class to itself. Analysts covering it are spread from $17.00 to $57.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell SNDX?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revuforj no longer has the menin inhibitor class to itself. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $17.00, +95.0% from the $8.72 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for SNDX?
+
Revuforj moving from KMT2A into the far larger NPM1 population. The original November 2024 approval covered KMT2A-rearranged acute leukemia, a genuinely rare subset. The most optimistic analyst target on SNDX is $57.00, +553.7% from the $8.72 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for SNDX?
+
Revuforj no longer has the menin inhibitor class to itself. Kura Oncology and Kyowa Kirin won FDA approval for ziftomenib (Komzifti) in November 2025 in relapsed or refractory NPM1-mutated AML, the same population Syndax entered three weeks earlier, and began selling on November 21, 2025. Komzifti is dosed once daily. Both labels carry boxed warnings, including differentiation syndrome and QTc prolongation, so the competition is likely to be fought on dosing convenience, payer access and combination data rather than on a clean safety separation. Kura's partner paid $330M upfront with up to $1.1B in milestones, which funds a serious commercial effort against a Syndax field force that is already carrying two products. Johnson & Johnson and Sumitomo also have menin inhibitors in development. The balance sheet is the second issue. Total stockholders' equity was $15.1M at June 30, 2026 against $688.6M of liabilities, and the accumulated deficit stands at about $1.6B; trailing net losses of ~$209M have eroded that thin cushion further since. The financing is unusual in shape: a $350M upfront from Royalty Pharma in November 2024 that sells 13.8% of US Niktimvo net sales with aggregate payments capped at $822.5M, accounted for as debt, plus $250M of 2.25% convertible senior notes due June 2031 issued in June 2026 at a conversion price near $24.76. Royalty interest expense alone was $12.1M in the second quarter and $24.0M for the half, and it grows as Niktimvo grows. If Niktimvo performs, Syndax pays back up to 2.35 times what it received. The converts add about 10.1M potential shares against 89.4M outstanding. Beyond that, revenue depends on two products in narrow later-line indications, both under UCB and AbbVie-related royalty obligations, with the frontline expansions still unproven. The first quarter of 2026 already showed how sensitive the line is to the January payer reset, falling to $64.9M from $68.7M in the fourth quarter of 2025 despite underlying demand growth. Pipeline risk has already shown up once. The MAXPIRe Phase 2 trial in idiopathic pulmonary fibrosis (145 patients, 26 weeks, axatilimab 0.3 mg/kg every two weeks against placebo) missed its primary endpoint on October 12, 2026, though safety was comparable to placebo. Syndax said the result does not affect trials in other indications, and BofA cut its target to $23 from $26 while keeping a Buy rating. The second readout that mattered, axatilimab plus ruxolitinib in frontline cGVHD, then slipped to the first quarter of 2027, and the company is also going through a chief financial officer transition. The third-quarter loss of $0.55 a share missed the ~$0.48 consensus, the second miss in a row, and the shares fell from ~$13.11 on October 16 to ~$8.95 on November 20, 2026, close to the 52-week low of ~$8.41. UBS cut its target to $31 from $33 on November 20 while keeping a Buy rating. The most pessimistic published target is $17.00, +95.0% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Syndax Pharmaceuticals do?
+
Syndax Pharmaceuticals sells two approved medicines, Revuforj in acute leukemia and Niktimvo in chronic GVHD, the latter partnered with Incyte.
What would have to change for SNDX to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Revuforj moving from KMT2A into the far larger NPM1 population) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (revuforj no longer has the menin inhibitor class to itself) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Syndax Pharmaceuticals do?
+
Syndax is a commercial-stage biopharmaceutical company headquartered in New York that develops and sells cancer and immune-mediated disease therapies. It has two FDA-approved medicines. Revuforj (revumenib) is an oral menin inhibitor approved in November 2024 for relapsed or refractory acute leukemia with a KMT2A translocation and expanded in October 2025 into relapsed or refractory AML with a susceptible NPM1 mutation. Niktimvo (axatilimab-csfr) is an antibody blocking the CSF-1 receptor, approved in August 2024 for chronic graft-versus-host disease after at least two prior lines of systemic therapy. Behind those, Syndax is running Phase 3 trials to move revumenib into newly diagnosed AML and testing axatilimab in frontline cGVHD; a Phase 2 in idiopathic pulmonary fibrosis missed its primary endpoint in October 2026 and that program has been dropped. Two earlier-stage programmes, an allosteric EGFR inhibitor for lung cancer and a next-generation menin inhibitor for myelofibrosis, are targeted for INDs in 2027.
Why is SNDX revenue lower than its drug sales?
+
Because only one of the two drugs flows through as product revenue. Syndax partnered axatilimab with Incyte in September 2021, and under accounting rules for collaboration arrangements Incyte is the principal in product sales. Incyte therefore records all Niktimvo revenue, and Syndax records only its 50% share of net commercial profit, defined as net product revenue minus cost of sales and commercial expenses. In the third quarter of 2026 that meant about $67M of Niktimvo net sales produced $22.6M of collaboration revenue at Syndax. Revuforj, which Syndax owns outright in the US, is recorded gross at about $61M in the same quarter. Anyone computing price-to-sales or gross margin from the reported top line is mixing a gross number with a net-of-costs profit share, which makes both ratios non-comparable to a conventional specialty pharmaceutical company.
Is SNDX profitable?
+
No. Syndax reported a net loss of $49.4M, or $0.55 per share, in the third quarter of 2026, the same as in the second quarter, and about $209.5M over the trailing twelve months. Full-year 2025 was a $285.4M loss and 2024 was $318.8M. The trend has improved: the operating loss narrowed from $153.1M in the first half of 2025 to $74.2M in the first half of 2026, because revenue more than doubled while total operating expenses stayed essentially flat at around $212M. Operating cash burn fell from $183.0M to $80.6M over the same comparison. Management has said it expects existing cash together with product revenue, collaboration revenue and interest income to carry the company to profitability, but no target date has been given, analysts still expect a loss of ~$0.65 a share in 2027, and the accumulated deficit stands at roughly $1.6B.
Walnut is informational, not investment advice, and gives no verdict on SNDX. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.